Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01116440 · ClinicalTrials.gov registry record · Phase 2
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
A Phase 2 study, sponsored by Mereo BioPharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01116440 is a Phase 2 study that was terminated before completion, run by Mereo BioPharma. The registered enrollment target is 27 participants.
The verdict
NCT01116440, a Phase 2 study, was terminated before completion, sponsored by Mereo BioPharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory endometriosis
Interventions
- DRUG Placebo
- DRUG BGS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-04-15 |
| Est. Completion | 2012-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01116440
The ClinicalTrials.gov registry entry for NCT01116440 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01116440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01116440 about?
NCT01116440 is a clinical study titled "A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis". The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory endometriosis
What is the current status of trial NCT01116440?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-04-15. Estimated completion is 2012-03-21.
What interventions are being tested in trial NCT01116440?
The interventions under investigation include: Placebo (DRUG), BGS649 (DRUG).
Who is sponsoring clinical trial NCT01116440?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.